title: In response to Drs. Dubben, Beck-Bornholdt, and Llogie.
authors.forename: K Kian
authors.initials: KK
authors.lastname: Ang
authors.forename: Brian A
authors.initials: BA
authors.lastname: Berkey
authors.forename: Thomas F
authors.initials: TF
authors.lastname: Pajak
authors.forename: Karen K
authors.initials: KK
authors.lastname: Fu
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use; D017326:Clinical Trials, Phase III as Topic; D003131:Combined Modality Therapy; D019583:Dose Fractionation, Radiation; D006258:Head and Neck Neoplasms / Q000532:radiotherapy*; D006801:Humans; D011832:Radiation Injuries / Q000209:etiology*; D011878:Radiotherapy / Q000009:adverse effects; D016032:Randomized Controlled Trials as Topic; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents